Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine in stable coronary artery disease (ECLIPSE)
NCT06567678Phase 1Completed
- Sponsor
- The University of the West Indies
- Start
- Aug 2024
- Primary completion
- Oct 2024
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of colchicine in coronary artery disease (CAD), sponsored by The University of the West Indies. Primary endpoints: P2Y12 reaction units at 2 weeks and Aspirin reaction units at 2 weeks. Started Aug 2024; status: completed.
02
Drugs
colchicine
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT06567678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06567678.